Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... Six startups from Russia traveled ... as part of the U.S.-Russia Innovation Corridor (USRIC) ... biotechnology startups to participate in the program since ... the University of Maryland (UMD) signed a Memorandum ... universities in the biomedical industry in 2013. , ...
(Date:4/23/2015)... SAN FRANCISCO, Calif. , April 23, 2015  Veracyte, ... has entered into a definitive agreement to sell approximately ... placement. Under the agreement, the investors will purchase an ... purchase price of $8.15 per share, the closing stock ... led by new and existing investors, including Broadfin Capital, ...
(Date:4/23/2015)... 2015  Propanc Health Group Corporation (OTCBB: PPCH) ... the development of cancer treatments for patients with ... includes PRP, a patented formulation consisting of two ... as the enzyme amylase designed to synergistically enhance ... of anti-cancer agents working in combination with pro-enzymes, ...
(Date:4/22/2015)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ) today reported ... For the first quarter ended March 31, 2015, ... or $0.08 per share, compared to a net loss ... same period in 2014. As of March 31, 2015, ... interest receivable of $226.1 million. Revenues for ...
Breaking Biology Technology:U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 2Sangamo BioSciences Reports First Quarter 2015 Financial Results 3Sangamo BioSciences Reports First Quarter 2015 Financial Results 4Sangamo BioSciences Reports First Quarter 2015 Financial Results 5Sangamo BioSciences Reports First Quarter 2015 Financial Results 6Sangamo BioSciences Reports First Quarter 2015 Financial Results 7Sangamo BioSciences Reports First Quarter 2015 Financial Results 8
... 23 Cordex Pharma, Inc., formerly known as Duska Therapeutics, ... host a scientific briefing on Thursday, January 29, 2009, at ... will be Jonathan S. Stamler, MD, the George Barth Geller ... Medicine and of Biochemistry at Duke University Medical ...
... MENLO PARK, Calif., Jan. 23 XTENT, Inc. (Nasdaq: ... an investment bank to help the company pursue strategic alternatives ... the company,s assets or other types of merger or acquisition ... in the capital markets, we believe it is in the ...
... P2R Associates today announced it,received eight prestigious ... Communication Professionals. The awards were presented,recognizing outstanding ... 5,000 entries from throughout the U.S. and several,foreign ... honored to be recognized for our work," said ...
Cached Biology Technology:Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 2Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 3Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 4Cordex Pharma Presents 'New Frontiers in Cardiovascular Medicines' on January 29 5XTENT to Retain Investment Bank to Pursue Strategic Alternatives 2XTENT to Retain Investment Bank to Pursue Strategic Alternatives 3P2R Associates Presented with Eight MarCom Awards for Client Strategic Communication Programs 2
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
(Date:3/23/2015)... --  HOYOS Labs , a leading global authentication infrastructure ... Company will demonstrate multiple biometrics-based technologies under its identity ... on March 23 through 25, 2015, in ... IEEE Biometric Open Protocol Standard; free biometrics-based consumer app, ... system. BOPS was invented by HOYOS Labs and contributed ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... PROVIDENCE, R.I. [Brown University] In recent years, researchers ... soldiers returning home from battlefields in Afghanistan or Iraq ... have trouble keeping bacteria from entering the body through ... "You need to close (the area) where the bacteria ...
... and storage intensifies as scientists from the Earth Sciences ... examine the capacity for storing carbon dioxide underground, in ... Greenhouse Gases: Science & Technology . The ... earlier study by Ehlig-Economides and Economides1, countering their claims ...
... Bryozoa. Earlier studies were based on visible characteristics of these ... are related to each other. To understand the evolution of ... is necessary to use molecular data, that,s to say DNA," ... University of Gothenburg. When Bryozoa were discovered in the ...
Cached Biology News:Nanomodified surfaces seal leg implants against infection 2Carbon capture and storage: Carbon dioxide pressure dissipates in underground reservoirs 2Unknown animals nearly invisible but yet there 2
... 3.1.21.1) is a nonspecific endonuclease that degrades ... by hydrolyzing phosphodiester linkages, producing mono and ... group. Ambion's RNase-free DNase I is of ... to degrade DNA in the presence of ...
RABBIT ANTI RHEB (IN) Immunogen: A 15 amino acid peptide located in the central region of human Rheb....
... GELase™ Agarose Gel-Digesting Preparation contains a ... for simple, quantitative recovery of intact DNA ... agarose gels following electrophoresis in TAE, TBE, ... be digested directly in the TAE, TBE, ...
... Gel-Digesting Preparation contains a unique β-agarose digesting ... recovery of intact DNA and RNA from ... electrophoresis in TAE, TBE, MOPS, or phosphate ... in the TAE, TBE, MOPS, and phosphate ...
Biology Products: